Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;9(3):257-62.
doi: 10.4306/pi.2012.9.3.257. Epub 2012 Sep 6.

Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study

Dong-Ho Song  1 , Soul Choi, Yoo Sook Joung, Eun Hye Ha, Boong-Nyun Kim, Yee-Jin Shin, Dongwon Shin, Hee Jeong Yoo, Keun-Ah Cheon
Affiliations

Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study

Dong-Ho Song et al. Psychiatry Investig. 2012 Sep.

Abstract

Objective: This study was aimed to determine effectiveness and tolerability of Osmotic-controlled Release Oral delivery (OROS) methylphenidate (MPH) and its optimal dose administered openly over a period of up to 12 weeks in drug naïve Korean children with ADHD.

Methods: Subjects (n=143), ages 6 to 18-years, with a clinical diagnosis of any subtype of ADHD were recruited from 7 medical centers in Korea. An individualized dose of OROS-MPH was determined for each subject depending on the response criteria. The subjects were assessed with several symptom rating scales in week 1, 3, 6, 9 and 12.

Results: 77 of 116 subjects (66.4%) achieved the criteria for response and the average of optimal daily dose for response was to 30.05±12.52 mg per day (0.90±0.31 mg/kg/d) at the end of the study. Optimal dose was not significantly different between ADHD subtypes, whereas, significant higher dose was needed in older aged groups than younger groups. The average of optimal daily dose for response for the subjects aged above 12 years old was 46.38±15.52 per day (0.81±0.28 mg/kg/d) compared to younger groups (p<0.01). No serious adverse effects were reported and the dose did not have a significant effect on adverse effects.

Conclusion: Optimal mean dose of OROS-MPH was significantly different by age groups. Higher dose was needed in older aged groups than younger groups. Effectiveness and tolerability of OROS-MPH in symptoms of ADHD is sustained for up to 12 weeks.

Keywords: ADHD; OROS-MPH; Optimal dose.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Average daily dose of OROS methylphenidate by week. OROS: Osmotic-controlled Release Oral delivery.
See this image and copyright information in PMC

References

    1. Wilens TE, Bierderman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann Rev Med. 2002;53:113–131. - PubMed
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association; 1994.
    1. Barkley R, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546–557. - PubMed
    1. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50:565–576. - PubMed
    1. Lilienfeld S, Waldman ID. The relation between childhood attention-deficit hyperactivity disorder and adult antisocial behavior reexamined: the problem of heterogeneoity. Clin Psychol Rev. 1990;10:699–725.

LinkOut - more resources